[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA1197783A - Nasal pharmaceutical compositions - Google Patents

Nasal pharmaceutical compositions

Info

Publication number
CA1197783A
CA1197783A CA000420539A CA420539A CA1197783A CA 1197783 A CA1197783 A CA 1197783A CA 000420539 A CA000420539 A CA 000420539A CA 420539 A CA420539 A CA 420539A CA 1197783 A CA1197783 A CA 1197783A
Authority
CA
Canada
Prior art keywords
composition according
agent
nasal
ciliary function
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000420539A
Other languages
English (en)
French (fr)
Inventor
Jean-Rene Kiechel
Danielle Plas
Francoise Acezat-Mispelter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Application granted granted Critical
Publication of CA1197783A publication Critical patent/CA1197783A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA000420539A 1982-02-01 1983-01-31 Nasal pharmaceutical compositions Expired CA1197783A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8202781 1982-02-01
GB8202781 1982-02-01

Publications (1)

Publication Number Publication Date
CA1197783A true CA1197783A (en) 1985-12-10

Family

ID=10528017

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000420539A Expired CA1197783A (en) 1982-02-01 1983-01-31 Nasal pharmaceutical compositions

Country Status (27)

Country Link
JP (1) JPS58134017A (fi)
AT (1) AT385656B (fi)
AU (1) AU565613B2 (fi)
BE (1) BE895750A (fi)
CA (1) CA1197783A (fi)
CH (1) CH653555A5 (fi)
DE (1) DE3302949A1 (fi)
DK (1) DK164771C (fi)
ES (1) ES8502865A1 (fi)
FI (1) FI81258C (fi)
FR (1) FR2539994B1 (fi)
GR (1) GR81320B (fi)
HK (1) HK59989A (fi)
HU (1) HU191512B (fi)
IE (1) IE54532B1 (fi)
IL (1) IL67822A (fi)
IT (1) IT1197558B (fi)
KE (1) KE3888A (fi)
LU (1) LU84613A1 (fi)
MY (1) MY8700766A (fi)
NL (1) NL192325C (fi)
NZ (1) NZ203117A (fi)
PH (1) PH22198A (fi)
PT (1) PT76166B (fi)
SE (1) SE454402B (fi)
SG (1) SG34389G (fi)
ZA (1) ZA83673B (fi)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009019463A1 (en) * 2007-08-06 2009-02-12 Britannia Pharmaceuticals Limited Powdered medicament for nasal delivery of ascorbic acid for reducing apomorphine induced toxicity to ciliated tissue

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910375D0 (en) * 2009-06-16 2009-07-29 Biocopea Ltd Drug composition and its use in therapy
US20190209463A1 (en) * 2018-01-05 2019-07-11 Impel Neuropharma, Inc. Intranasal delivery of dihydroergotamine by precision olfactory device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091569A (en) * 1960-08-26 1963-05-28 Mead Johnson & Co Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus
GB1202885A (en) * 1966-12-22 1970-08-19 Sandoz Ltd Pharmaceutical compositions comprising alkaloids
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
FR2387035A1 (fr) * 1977-04-12 1978-11-10 Cassenne Lab Sa Nouveau medicament destine notamment au traitement des troubles fonctionnels cerebraux
DE2831728C2 (de) * 1978-07-19 1982-12-23 Krewel-Werke Gmbh, 5208 Eitorf Arzneimittel zur Behandlung von Kopfschmerzen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009019463A1 (en) * 2007-08-06 2009-02-12 Britannia Pharmaceuticals Limited Powdered medicament for nasal delivery of ascorbic acid for reducing apomorphine induced toxicity to ciliated tissue

Also Published As

Publication number Publication date
AT385656B (de) 1988-05-10
NZ203117A (en) 1986-12-05
MY8700766A (en) 1987-12-31
HK59989A (en) 1989-08-04
NL192325B (nl) 1997-02-03
SG34389G (en) 1989-09-22
NL192325C (nl) 1997-06-04
JPH0253406B2 (fi) 1990-11-16
PH22198A (en) 1988-06-28
ES519450A0 (es) 1985-02-01
AU1085083A (en) 1983-08-11
DE3302949A1 (de) 1983-08-11
HU191512B (en) 1987-02-27
JPS58134017A (ja) 1983-08-10
SE8300495D0 (sv) 1983-01-31
IL67822A0 (en) 1983-06-15
KE3888A (en) 1989-09-01
NL8300325A (nl) 1983-09-01
GR81320B (fi) 1984-12-11
FR2539994A1 (fr) 1984-08-03
LU84613A1 (fr) 1983-09-08
IE54532B1 (en) 1989-11-08
DK38183A (da) 1983-08-02
PT76166A (en) 1983-02-01
SE454402B (sv) 1988-05-02
FI830245A0 (fi) 1983-01-25
IT8347646A0 (it) 1983-02-01
BE895750A (fr) 1983-08-01
CH653555A5 (de) 1986-01-15
DK164771B (da) 1992-08-17
DK38183D0 (da) 1983-01-31
ATA30383A (de) 1987-10-15
FI81258B (fi) 1990-06-29
FI830245L (fi) 1983-08-02
IL67822A (en) 1988-02-29
DE3302949C2 (fi) 1992-05-21
SE8300495L (sv) 1983-08-02
ES8502865A1 (es) 1985-02-01
PT76166B (en) 1986-02-04
FR2539994B1 (fr) 1986-10-10
AU565613B2 (en) 1987-09-24
IE830187L (en) 1983-08-01
ZA83673B (en) 1984-09-26
FI81258C (fi) 1990-10-10
IT1197558B (it) 1988-12-06
DK164771C (da) 1992-12-28

Similar Documents

Publication Publication Date Title
US5169849A (en) Nasal pharmaceutical compositions
RU2421209C2 (ru) Фармацевтические композиции, содержащие циклоспорин
ES2384384T3 (es) Formulaciones inhalables para tratar la hipertensión pulmonar y procedimientos de uso de las mismas
JP3830158B2 (ja) 禁煙補助組成物
HUE031470T2 (en) Preparations and methods of use containing azelastine
RU2255736C2 (ru) Фармацевтические композиции, содержащие золмитриптан
EA002174B1 (ru) Фармацевтические композиции, содержащие гемисульфат элетриптана и кофеин
JP2019520361A (ja) アルコール使用障害の処置のための組成物、装置、及び、方法
ES2395130T3 (es) Método y composición para el tratamiento de rinitis
US6740306B2 (en) Imidazotriazinone-containing compositions for nasal administration
CA2619863A1 (en) Use of ambroxol for the treatment of rhinovirus infections
US4885305A (en) Nasal compositions
CA1197783A (en) Nasal pharmaceutical compositions
GB2114001A (en) Nasal pharmaceutical compositions
US20230320978A1 (en) Compositions and methods for lowering intracranial pressure
WO1996000071A1 (en) Treatment of nicotine craving and/or smoking withdrawal symptoms with a liquid nasal composition containing nicotine and caffeine or xanthine
ES2935684T3 (es) Formulaciones de epinefrina intranasales y métodos para el tratamiento de enfermedades
WO1996000069A1 (en) Treatment of nicotine craving and/or smoking withdrawal symptoms with a solid or semi-solid composition containing nicotine and caffeine or xanthine, especially for nasal administration
US20040142944A1 (en) Compositions for nasal application
Jadhav et al. NASAL DRUG DELIVERY SYSTEM: A ROUTE FOR BRAINE TARGETTING
KR20010014366A (ko) 엘레트립탄 헤미술페이트 및 카페인을 포함하는 약제학적조성물
BR112012007087A2 (pt) composições farmacêuticas compreendendo compostos triptano e uso das mesmas para a preparação de um medicamento para tratar condições associadas à dor cefálica

Legal Events

Date Code Title Description
MKEC Expiry (correction)
MKEX Expiry